PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis

Journal of Neuroimmunology

Volumn 197, Issue 2, 2008, Pages 110-113

  Lefvert, Ann Kari ^a   Zhao, Yaofeng ^a   Ramanujam, Ryan ^a   Yu, Shuyang ^a   Pirskanen, Ritva ^a   Hammarström, Lennart ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acetylcholine receptor; Gravis; Myasthesia; PTPN22

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; INTERLEUKIN 2;

ALLELE; ARTICLE; CASE CONTROL STUDY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; INCUBATION TIME; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYASTHENIA GRAVIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANALYSIS OF VARIANCE; ARGININE; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; MALE; MYASTHENIA GRAVIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; RECEPTORS, CHOLINERGIC; SWEDEN; TRYPTOPHAN;

EID: 46649095805     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.04.004     Document Type: Article

References (14)

1. Bottini N., Musumeci L., Alonso A., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36 (2004) 337-338
2. Botinni N., Vang T., Cucca F., and Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 18 4 (2006) 207-213
3. Hasegawa K., Martin F., Huang G., et al. PEST domain-enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303 (2004) 685-689
4. Heward J.M., Brand O.J., Barrett J.C., et al. Association of PTPN22 haplotypes with Graves' disease. J. Clin. Endocrinol. Metab. 92 (2007) 685-690
5. Garchon H.J. Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man. J. Autoimmun. 21 (2003) 105-110
6. Gregersen P.K. Gaining insight into PTPN22 and autoimmunity. Nat. Genet. 37 (2005) 1300-1302
7. Gregersen P.K., Lee H.S., Batliwalla F., and Begovich A.B. PTPN22: Setting thresholds for autoimmunity. Semin. Immunol. 18 4 (2006) 214-223
8. Lefvert A.K., Bergstrom K., Matell G., et al. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J. Neurol. Neurosurg.Psychiatry 41 (1978) 394-403
9. Poea-Guyon S., Christadoss P., Le Panse R., et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J. Immunol. 174 (2005) 5941-5949
10. Vang T., Congia M., Macis M.D., et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37 (2005) 1317-1319
11. Vandiedonck C., Capdevielle C., Giraud M., et al. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann. Neurol. 59 (2006) 404-407
12. Wang X.B., Kakoulidou M., Giscombe R., et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neuroimmunol. 130 (2002) 224-232
13. Yamamoto A.M., Gajdos P., Eymard B., et al. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch. Neurol. 58 (2001) 885-890
14. Yi Q., Pirskanen R., and Lefvert A.K. Human muscle acetylcholine receptor reactive T and B lymphocytes in the peripheral blood of patients with myasthenia gravis. J. Neuroimmunol. 42 (1993) 215-222